DK1144010T3 - Forebyggelse af kronisk transplantatafstödning ved hjælp af en kombination af immuntoksiner og costimuleringsblokkere - Google Patents

Forebyggelse af kronisk transplantatafstödning ved hjælp af en kombination af immuntoksiner og costimuleringsblokkere

Info

Publication number
DK1144010T3
DK1144010T3 DK00904230T DK00904230T DK1144010T3 DK 1144010 T3 DK1144010 T3 DK 1144010T3 DK 00904230 T DK00904230 T DK 00904230T DK 00904230 T DK00904230 T DK 00904230T DK 1144010 T3 DK1144010 T3 DK 1144010T3
Authority
DK
Denmark
Prior art keywords
recipient
transplant
administering
combination
immunotoxins
Prior art date
Application number
DK00904230T
Other languages
English (en)
Inventor
Stuart J Knechtle
Allan D Kirk
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of DK1144010T3 publication Critical patent/DK1144010T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00904230T 1999-01-08 2000-01-06 Forebyggelse af kronisk transplantatafstödning ved hjælp af en kombination af immuntoksiner og costimuleringsblokkere DK1144010T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11525299P 1999-01-08 1999-01-08
PCT/US2000/000284 WO2000040270A2 (en) 1999-01-08 2000-01-06 Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28

Publications (1)

Publication Number Publication Date
DK1144010T3 true DK1144010T3 (da) 2007-09-03

Family

ID=22360179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904230T DK1144010T3 (da) 1999-01-08 2000-01-06 Forebyggelse af kronisk transplantatafstödning ved hjælp af en kombination af immuntoksiner og costimuleringsblokkere

Country Status (9)

Country Link
EP (1) EP1144010B1 (da)
AT (1) ATE359826T1 (da)
AU (1) AU768547B2 (da)
CA (1) CA2358435A1 (da)
DE (1) DE60034428T2 (da)
DK (1) DK1144010T3 (da)
ES (1) ES2286006T3 (da)
PT (1) PT1144010E (da)
WO (1) WO2000040270A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
AU733898B2 (en) 1997-03-05 2001-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxins and methods of inducing immune tolerance
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191733A1 (en) * 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
CA2218166C (en) * 1995-04-14 2012-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
AU733898B2 (en) * 1997-03-05 2001-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxins and methods of inducing immune tolerance
BR9809641A (pt) * 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
WO1998056417A1 (en) * 1997-06-11 1998-12-17 The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
EP1073463B1 (en) * 1998-04-22 2009-07-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation

Also Published As

Publication number Publication date
AU2601700A (en) 2000-07-24
WO2000040270A2 (en) 2000-07-13
EP1144010B1 (en) 2007-04-18
CA2358435A1 (en) 2000-07-13
DE60034428T2 (de) 2008-01-03
WO2000040270A3 (en) 2001-10-18
PT1144010E (pt) 2007-07-20
ES2286006T3 (es) 2007-12-01
AU768547B2 (en) 2003-12-18
ATE359826T1 (de) 2007-05-15
DE60034428D1 (de) 2007-05-31
EP1144010A2 (en) 2001-10-17
EP1144010A3 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
WO2001077299A3 (en) A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
NZ527076A (en) Graft rejection inhibitors used in combination with immunosuppressants
MA27177A1 (fr) Synthese controlee de ziprasidone et compositions en contenant.
DK0881901T3 (da) Kombination af aktive stoffer, der indeholder clopidogrel og et antithrombotisk middel
HK1046296A1 (en) Lubricating oil compositions and watch containing the same.
EP0641112A3 (en) Telephone routing system with queuing and voicemail capabilities.
NL1016224A1 (nl) Foto-basevormend middel en foto-zuurvormend middel bevattende foto- etssamenstelling.
PL311594A1 (en) Agent for protecting silver i against corrosion
MXPA03004116A (es) Copolimero de bloque, composicion del mismo, y pelicula obtenida del mismo.
UA29398C2 (uk) Антимікробний перкислотний склад (варіанти)
NO976031L (no) Lavviskös, höykonsentrert friksjonsreduserende middel og fremstilling derav
TR199600800T1 (tr) Ergimis haldeki metale daldirilan sonda.
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
KR950701006A (ko) 질소함유 소결경질합금(nitrogen-containing hard sintered alloy)
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
DK1144010T3 (da) Forebyggelse af kronisk transplantatafstödning ved hjælp af en kombination af immuntoksiner og costimuleringsblokkere
DE50103006D1 (de) Mikrobizid wirksame tenside
WO2001058526A3 (en) Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
AU4661701A (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants
ES2154018T3 (es) Soluciones inyectables por via parenteral que contienen piroxicam.
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
HK1045813B (zh) 局部敷用的含甘油及斗篷草精華的非固體合成劑
EP0615226A3 (en) Method for noise reduction in disturbed voice drannels.
DK0896532T3 (da) Acylurinstofforbindelser til behandling af coccidioidomycose i varmblodede dyr
GB9802542D0 (en) New use